Skip to main content

Table 4 Adjusted HRs of cardiovascular outcomes across the spectrum of HbA1c and NT-proBNP categories

From: The joint association of diabetes status and NT-ProBNP with adverse cardiac outcomes in patients with non-ST-segment elevation acute coronary syndrome: a prospective cohort study

HbA1c category

NT-proBNP

T1 (< 92 pg/ml)

T2 (92–335 pg/ml)

T3 (≥ 336 pg/ml)

P value for trend

n/N

HR (95% CI) *

n/N

HR (95% CI) *

n/N

HR (95% CI) *

MACCEs

       

 < 5.7%

39/798

Ref.

58/719

1.28 (0.85–1.93)

130/641

2.19 (1.50–3.20)

 < 0.001

 5.7–6.4%

69/978

1.44 (0.97–2.14)

88/962

1.46 (1.00–2.15)

211/954

2.41 (1.67–3.47)

 < 0.001

 ≥ 6.5%

73/877

1.71 (1.16–2.53)

144/974

2.40 (1.67–3.46)

258/1053

2.72 (1.89–3.91)

 < 0.001

 P value for trend

 

0.357

 

0.001

 

 < 0.001

 

All-cause mortality

       

 < 5.7%

11/798

Ref.

12/719

0.71 (0.31–1.62)

76/641

2.42 (1.25–4.69)

 < 0.001

 5.7–6.4%

11/978

0.75 (0.33–1.74)

24/962

0.99 (0.48–2.04)

118/954

2.26 (1.18–4.34)

 < 0.001

 ≥ 6.5%

12/877

0.92 (0.40–2.09)

51/974

2.07 (1.06–4.03)

146/1053

2.92 (1.53–5.57)

 < 0.001

 P value for trend

 

0.048

 

0.333

 

 < 0.001

 
  1. *Estimates were adjusted for age, sex, BMI, NSTE-ACS status, previous hypertension, previous dyslipidemia, previous myocardial infarction, systolic blood pressure, heart rate, LVEF, eGFR, hs-CRP, LDL-C, smoking status, and in-hospital treatments (PCI, antiplatelet therapy, β-blocker, ACEI or ARB, and statins); Statistically significant estimates in bold
  2. Abbreviations see Table 1